The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -509,940 | -1,591,844 |
| Share-based expense | 15,855 | 34,934 |
| Prepaid expenses and other | 372,507 | 151,900 |
| Other assets | 0 | -313,921 |
| Accounts payable, accrued expenses and other liabilities | 208,345 | 9,167 |
| Net cash used in operating activities | -658,247 | -1,385,722 |
| Net change in cash | -658,247 | -1,385,722 |
| Cash and cash equivalents at beginning of period | 6,165,568 | - |
| Cash and cash equivalents at end of period | 4,121,599 | - |
Xenetic Biosciences, Inc. (XBIO)
Xenetic Biosciences, Inc. (XBIO)